G eneration of the serine protease thrombin is the key event in hemostasis and of vital importance for clot formation and thrombotic vessel occlusion after vascular injury. 1, 2 This involves a combined action of the enzyme on circulating zymogens of clotting factors as well as a receptor-mediated stimulation of platelet aggregation and contraction of vascular SMC. Activation of protease-dependent receptors resulting in the generation of a tethered ligand after binding of thrombin to its receptor allows one molecule of thrombin to activate many thrombin receptors. 3, 4 These findings have stimulated the search for control mechanisms that determine the specificity of this response and focus the biological action of thrombin to specific cellular targets.
One issue of particular relevance in the pathophysiology of thrombin actions is the relationship between thrombininduced clot formation and mitogenic activity. It has been shown that SMC proliferation occurring in an area of thrombotic arterial vessel occlusion is related to the size and place of the preexisting thrombus. 5, 6 The thrombus contains complex materials such as peptidergic growth factors, serotonin, and active thrombin that can be released into the vessel lumen and may facilitate vasoconstriction and tissue proliferation in an area with endothelial injury. Importantly, enzymatically active ␣-thrombin 7 will escape inactivation by circulating antithrombins after binding within the clot 8 or subendothelial matrix. 5, 9 This thrombin might further stimulate platelets or the clotting cascade and maintains its activity over hours. 10 In addition, enzymatically active thrombin is a potent direct mitogen for SMC. 10 -15 This effect is antagonized by direct thrombin inhibitors such as hirudin. 10 Thus the mitogenic action of thrombin in vivo might result from both a direct action on SMC and thrombin-induced generation of platelet-derived mitogenic factors in the thrombus.
One such thrombus-related factor is TXA 2 . Blood platelets are the natural source of TXA 2 in the circulation. Previous studies have addressed the question of whether or not TXA 2 or appropriate agonists can induce SMC proliferation. In some studies, TXA 2 mimetics, such as U 46619, CTA 2 , STA 2 or I-BOP, can stimulate proliferation of vascular SMC, 16 -21 partially doing so by upregulating the synthesis and release of endogenous growth factors such as platelet-derived growth factor (PDGF) or basic fibroblast growth factor (bFGF) 20 and by a synergistic action with peptidergic growth factors in intracellular signal transduction via the MAP kinase pathway. 19, 21 In contrast, other investigators did not detect direct mitogenic effects of TXA 2 on SMC. 22, 23 Part of the explanation may be different culture conditions. This includes the presence of fetal calf serum, 18, 19 species differences, as well as the source of SMC, which in many cases are derived from the aorta.
The number of TP receptors in platelets is regulated by hormones (testosterone), receptor agonists (thromboxane mimetics), peptidergic growth factors (PDGF), and disease states such as recurrent myocardial ischemia. 24 -26 Indirect evidence suggests that enhanced thrombin generation in blood might also increase the number of TP receptors at the platelet surface. 27 An upregulation of TP receptor mRNA by thrombin has also been demonstrated in a megakaryoblastic cell line. 28 There is also evidence for functional thromboxane receptors in vascular tissue, 29 although their regulation is much less understood. Thus the present data collectively suggest a synergistic interaction between thrombin and TXA 2 , possibly occurring at the level of thromboxane formation, intracellular signal transduction, and receptor regulation, respectively. This study investigates the interactions between thrombin and a chemically stable thromboxane mimetic, U 46619, on proliferation of bovine coronary artery SMC. Evidence is provided that U 46619 potentiates thrombin-induced mitogenesis and that this response involves thrombin-induced expression of TP receptors.
Methods

Cell Culture
Bovine SMC were isolated enzymatically from the left anterior descending coronary artery of adult female animals, following the method of Fallier-Becker et al. 30 The cells were cultivated in an 80% Ham's F-12/20% Dulbecco's modified eagle medium (DMEM), supplemented with 15% fetal calf serum (FCS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin (all cell culture material was from Gibco or Becton & Dickinson). Cells were grown in a humidified atmosphere of 5% CO 2 and 95% air at 37°C. SMC were characterized microscopically by the typical "hill-and-valley" growth pattern and by indirect immunostaining with a specific monoclonal ␣-actin antibody (Boehringer Mannheim). The media were exchanged twice a week. Monolayers of the cells were passaged on 150-mm tissue culture dishes once a week with trypsin (0.05%)/EDTA (0.5 mmol/L). Passages 4 to 10 were used for the experiments. Cell viability was assessed by means of trypan blue exclusion test and was found to be Ͼ95%.
DNA and Protein Synthesis
SMC were seeded into 24-well plates (5ϫ10 4 cells/well) and cultivated for 72 hours under standard conditions until subconfluency was reached. For the following 24 hours, cells were exposed to serum-free medium to allow defined stimulation with mitogens. All further incubations were also carried out in serum-free medium, supplemented with 3 mol/L indomethacin (Luitpold Pharma).
␣-Thrombin (1 U/mL), the TXA 2 mimetic U 46619 (Upjohn Diagnostics) (0.3 to 30 mol/L) and the thromboxane receptor antagonist SQ 29,548 (Bristol-Myers-Squibb Pharmaceuticals) (1 mol/L) were added to duplicate or triplicate wells. In additional experiments, hirudin (3 ATU/mL) was added 0 to 4 hours subsequent to stimulation with either thrombin alone or thrombin combined with U 46619, respectively.
After 
Determination of Number of Cells Entering S-Phase
DNA synthesis was assayed by immunofluorescence labeling of incorporated 5-bromo-2Ј-deoxyuridine (BrdU) with a cell proliferation kit (BrdU labeling and detection kit I, Boehringer Mannheim). Cells were grown on round glass microscope slides (diameter, 12 mm), serum-deprived, and stimulated with mitogens as described above. Twenty hours after addition of the agonists, BrdU incorporation was monitored according to the manufacturer's instructions. Representative areas of the slides were screened in a standardized way for nuclei stained positive for BrdU. At the time of the BrdU labeling, no differences in cell count (see below) were seen.
Cell Proliferation Assay
Cells were grown to Ϸ50% confluence, then made quiescent and stimulated with mitogens as described above. After 24 and 48 hours, respectively, cells were trypsinized and total cell number was assessed by counting the cells per well, using a hemocytometer.
Myelin Basic Protein Phosphorylation Assay
MAP kinase activity was assessed by the MBP phosphorylation assay as described by Huwiler et al. 32 Subconfluent, serum-deprived SMC were treated with indomethacin (3 mol/L) as described above. Thrombin was added to every second dish for 4 hours. Subsequently, cells were stimulated with U 46619 (3 mol/L) for 10 minutes. In some experiments, SMC were preincubated with SQ 29,548 (1 mol/L) for 2 minutes before stimulation with U 46619. After stimulation, SMC were washed with PBS and harvested into kinase buffer (20 mmol/L Tris/HCl, pH 7.5, 1 mmol/L EGTA, 2 mmol/L MgCl 2 , 0.1 mmol/L sodium orthovanadate, 1 mmol/L phenylmethylsulfonylfluoride, 25 g/mL leupeptin, and 1 g/mL pepstatin). Harvested cells were briefly sonicated and centrifuged for 5 minutes at 14 000g and 4°C. Cell extracts (60 g protein) were incubated for 15 minutes at 30°C in the presence of 20 g MBP (Sigma), 10 mol/L ATP, and 4 Ci [␥-32 P]-ATP (Hartmann Analytik). The reaction was terminated by addition of 4ϫ Laemmli buffer and heating of the samples for 5 minutes at 95°C. Proteins were separated by SDS/PAGE (13.5%), gels were fixed in 25% propan-2-ol/10% acetic acid, and bands were visualized by autoradiography.
RNA Analysis
TP receptor mRNA expression was analyzed by RT-PCR with total RNA from SMC prepared with trizol reagent (Gibco BRL), following standard methods. 33 First-strand cDNA was synthesized from total
Selected Abbreviations and Acronyms
MAP kinase ϭ mitogen-activated protein kinase MBP ϭ myelin basic protein RT-PCR ϭ reverse transcription-polymerase chain reaction SMC ϭ smooth muscle cell(s) TP ϭ thromboxane receptor(s) TXA 2 ϭ thromboxane A 2 RNA using oligo d(T) and murine leukemia virus reverse transcriptase (Perkin Elmer). The nucleotide sequence for the bovine prostaglandin H 2 /TXA 2 (TP) receptor has been deposited in the EMBL genebank database with the accession numbers U 53484 and U 53485, respectively. PCR primers were designed according to the cDNA sequence corresponding to the putative fourth and seventh transmembrane domain of the receptor (sense: 5Ј-TGGGGCGCTACACCGTG-CAG-3Ј; antisense: 5Ј-ATAGACCCAGGGATCCAAGA-3Ј). A glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) fragment of 238 bp length was amplified in addition to the 410 bp TP-receptor fragment (sense: 5Ј-TGATGACATCAAGAAGGTGGTGAAA-3Ј; antisense: 5Ј-TCCTTGGAGGCCATGTAGGCCAT-3Ј). PCRs were carried out using AmpliTaq DNA Polymerase (Perkin Elmer). After a 2-minute predenaturation step at 95°C, the reactions were cycled 30 times in a cycle profile of 1 minute at 95°C, 1.5 minutes at 57°C, and 2 minutes at 72°C, followed by a final extension step for 5 minutes at 72°C. The PCR products were analyzed by automated laser fluorescence with an ALF express sequencing system (Pharmacia Biotech).
Statistics
All data are meanϮSEM of n independent experiments, performed in duplicates or triplicates as indicated. Three-way ANOVA followed by linear contrasts and a Bonferroni-Holm procedure for multiple testings or one-way ANOVA followed by Bonferroni multiple comparison tests were used for statistical analysis. Values of PϽ.05 were considered significant.
Results
Potentiation of Thrombin-Induced Stimulation of DNA and Protein Synthesis by U 46619
Incubation of SMC with the stable TXA 2 mimetic U 46619 (0.3 to 30 mol/L) for 24 hours resulted only in a minor increase of DNA synthesis. Some stimulation (1.5-fold above control) was seen at 3 mol/L U 46619. Thrombin (1 U/mL) stimulated [ 3 H]thymidine incorporation 3-to 4-fold above control. Coincubation of thrombin (1 U/mL) with U 46619 resulted in a concentration-dependent stimulation of DNA synthesis at increasing concentrations of U 46619. For example, in the presence of 3 mol/L U 46619, thrombin-induced DNA synthesis was about twice as high as with thrombin alone, indicating a potentiation of thrombin-induced mitogenic reactions by the thromboxane mimetic. Further increase in U 46619 concentrations resulted in a disappearance of this effect. These data are summarized in Fig 1. A similar potentiation of thrombin-induced DNA synthesis by U 46619 was observed when the incorporation of BrdU was measured (Table) .
Similar results as for DNA synthesis were obtained when protein synthesis was measured by determination of 
Cell Proliferation
The effects of thrombin and/or U 46619 on SMC mitogenesis were further studied in a cell proliferation assay. At the time relevant for BrdU labeling (24 hours after stimulation), no differences in the cell count were observed between the groups. In contrast, 48 hours after addition of thrombin, a significant progression of the cell cycle into the M-phase was observed that was reflected by an increase in cell number. Again, thrombin-induced SMC proliferation was significantly amplified by U 46619. The data are summarized in the Table.
Inhibition of Thrombin-Induced Mitogenesis by Hirudin
SMC mitogenesis requires prolonged exposure to thrombin, and stimulation of DNA synthesis can be inhibited by addition of hirudin from 0 to 8 hours after stimulation with thrombin. 15 Therefore, we have studied the effects of a brief exposure to thrombin on U 46619 -induced SMC mitogenesis by inhibiting thrombin activity with hirudin from 0 to 4 hours after stimulation. When added up to 4 hours after stimulation, hirudin (3 ATU/mL) completely inhibited thrombin-induced DNA synthesis (Fig 4) .
When SMC were stimulated with thrombin and U 46619, immediate neutralization of thrombin with hirudin completely blocked the stimulation of DNA synthesis. Interestingly, when hirudin was added at later time points, a remarkable stimulation of DNA synthesis by U 46619 was observed that was dependent on the duration of thrombin exposure before neutralization with hirudin (Fig 4) . Since direct thrombin effects on DNA synthesis were completely inhibited by addition of hirudin within the time window studied, these results suggest a priming effect of thrombin on SMC resulting in an increased mitogenic responsiveness to U 46619.
Expression of TP Receptor mRNA
As a possible mechanism to explain the potentiation of thrombin-induced mitogenic effects by U 46619, we studied the hypothesis that TP receptors are upregulated by thrombin. Stimulation of quiescent SMC with thrombin (1 U/mL) for up to 3 hours resulted in a marked though transient increase in TP receptor mRNA expression. A maximum effect was seen at 20 minutes. At this time, thrombin stimulated TP receptor mRNA expression about sixfold above control. After continuous stimulation with thrombin for 3 hours, TP receptor mRNA expression returned to levels of unstimulated cells. 
MAP Kinase Activity
Experiments were performed to determine the effects of thrombin on the expression of TP receptor protein. Therefore, the level of TP receptor expression in SMC was assessed functionally by determination of MAP kinase activity (Fig 6) . In control cells, addition of U 46619 did not significantly stimulate MAP kinase activity. These data are consistent with a low basal TP receptor expression and are in line with our findings that U 46619 alone was not capable to stimulate DNA synthesis in SMC. However, when SMC were pretreated with thrombin for 4 hours, a marked stimulation of MAP kinase activity by U 46619 was seen (Fig 6) . This effect was inhibited by the TP receptor antagonist SQ 29,548. In concert with our findings on TP receptor mRNA, these data provide functional evidence for a thrombin-induced upregulation of TP receptors.
Discussion
The present data indicate that thrombin-induced mitogenesis of coronary artery SMC is markedly enhanced in the presence of a TXA 2 mimetic, which, alone, has only minor mitogenic activity. It is also shown that this potentiation of the thrombininduced response is TP receptor mediated because it is prevented by a selective antagonist. We have demonstrated a marked increase in thromboxane receptor mRNA in SMC and provided functional evidence for TP receptor upregulation by thrombin. These findings may provide a mechanistic basis for the proliferative responses to the two agonists.
Enzymatically active thrombin is a well-known mitogen in cultured vascular SMC. 10 -12,15,35 However, growth stimulation by thrombin is a slow-onset reaction, showing markedly delayed kinetics in the absence of serum or peptidergic growth factors. 4 For example, several days are necessary for thrombin to induce proliferation of bovine aortic SMC. 12 On the other hand, activation of transcription factors, such as c-fos or nuclear factor-B, occurs within a few hours after thrombin stimulation. 36 Similarly, phosphorylation of several signal transduction molecules, including MAP kinases, has been observed within minutes after thrombin stimulation. 37 Thus despite rapid thrombin receptor activation, the maximal mitogenic effect of thrombin in cultured SMC requires a prolonged exposure to active thrombin. 15 This was explained by a progressive thrombin-dependent recruitment of additional cells into the growth fraction. Alternatively, thrombin-induced mitogenesis in vivo might involve the generation or amplification of additional growth promoting signals, present in the thrombus or in the injured vessel wall in vivo but not in cultured SMC.
This study provides evidence for TXA 2 as an amplification signal for thrombin-induced SMC proliferation. As noted above, there are conflicting reports as to whether or not TXA 2 can stimulate mitogenesis. 16 -23 We have recently shown that thromboxane mimetics, such as U 46619, induce expression of immediate early genes, such as c-fos or egr-1, and potentiate PDGF-dependent responses in rat aortic SMC. 21 Similar data were obtained in SMC prepared from bovine coronary arteries. 38 The present study is the first to demonstrate that thrombin-induced mitogenic responses are potentiated by the thromboxane mimetic U 46619 in a receptor-dependent manner. First, U 46619, although a weak mitogen itself, markedly potentiated the mitogenic actions of thrombin. Second, the thromboxane component of this response was blocked by the specific thromboxane receptor antagonist SQ 29,548.
A possible explanation for the synergistic action between thrombin and U 46619 is that thrombin might regulate the expression of thromboxane receptors in SMC. A marked, sixfold increase in TP receptor mRNA levels was seen at 20 minutes. This is much earlier than the autoinduction of thrombin receptor mRNA expression in bovine or rat vascular SMC by thrombin. 15, 39 An upregulation of TP receptor gene expression by thrombin in a human megakaryoblastic cell line has been previously reported. Although TP receptor protein could not be detected by means of Western blotting or ligand binding studies probably because of low receptor protein expression, two lines of evidence support the concept of thrombin-induced upregulation of functional TP receptors in SMC. First, a brief (1.5 to 4 hours) incubation of SMC with thrombin resulted in an increased mitogenic responsiveness to U 46619 that was dependent on the duration of thrombin exposure before neutralization with hirudin. Second, SMC that have been treated with thrombin for 4 hours showed a markedly higher stimulation of MAP kinase by U 46619 compared with nontreated SMC. In concert with the demonstration of increased TP receptor mRNA expression by thrombin, these functional data provide strong evidence for an increased expression of functionally active TP receptors by thrombin. Because of the common pathways of thrombin-and TXA 2 -induced signaling, including MAP kinase activation, 19, 21, 37 an enhanced expression of thromboxane receptors is probably also translated into growth promoting signals within SMC. Accordingly, we have shown that cell proliferation (cell number 48 hours after stimulation) was potentiated by the combined use of thrombin and U 46619 compared with either agent alone.
Several in vivo studies indicate a synergistic procoagulatory effect between thrombin and TXA 2 during formation 40 and resolution 41 of thrombi within coronary arteries. There is also evidence for early upregulation of vascular thrombin receptors in vivo and in SMC tissue culture by peptidergic growth factors. 42 An increased number of prostaglandin H 2 /TXA 2 -receptors has been observed in platelets from patients with active unstable angina and was related to increased thrombin activity. 27 Inhibition of thrombin by hirudin in vivo significantly reduced platelet-rich thrombi and neointima proliferation in experimentally injured vessel segments. 6 These data suggest that active TXA 2 may be generated in platelet-rich thrombi long enough to enhance the mitogenic responses to thrombin. However, thromboxane formation may be limited by autoinactivation of platelet cyclooxygenase. 43 To address this possibility, we have measured plateletderived thromboxane formation in vitro under conditions similar to those associated with clot-related thromboxane formation in vivo (data not shown). In these studies, a marked, aspirin-sensitive thromboxane generation was found, persisting for at least 2 hours after addition of thrombin. This suggests continued cyclooxygenase and thromboxane synthase activity in the platelets over at least this period of time. Clearly, an increased thromboxane receptor number in SMC and associated thromboxane formation will act in concert and might synergize in thrombin-induced mitogenesis not only in vitro but also in vivo.
In summary, we have shown that thrombin-dependent upregulation of vascular TP receptors occurs in thrombinstimulated SMC and that active thromboxane potentiates proliferative thrombin responses. If these findings are translated into the in vivo situation, they would support the combination of selective thromboxane receptor antagonists in combination with thrombin inhibitors for prevention of SMC proliferation after coronary angioplasty. [44] [45] [46] 
